学術論文 原著・英文
1. Senda M, Ishii K, Ito K, Ikeuchi T, Matsuda H, Iwatsubo T, Iwata A, Ihara R, Suzuki K,
Kasuga K, Ikari Y, Niimi Y, Arai H, Tamaoka A, Arahata Y, Itoh Y, Tachibana H, Ichimiya Y,
Washizuka S, Odawara T, Ishii K, Ono K, Yokota T, Nakanishi A, Matsubara E, Mori H,
Shimada H. A Japanese multicenter study on PET and other biomarkers for subjects withpotential preclinical and prodromal Alzheimerʼs disease.

Journal of Prevention of

Alzheimers Disease (in press)
2. Okada R, Fujita SI, Suzuki R, Hayashi T, Tsubouchi H, Kato C, Sadaki S, Kanai M, Fuseya
S, Inoue Y, Jeon H, Hamada M, Kuno A, Ishii A, Tamaoka A, Tanihata J, Ito N, Shiba D,
Shirakawa M, Muratani M, Kudo T, Takahashi S.Transcriptome analysis of gravitationaleﬀects on mouse skeletal muscles under microgravity and artiﬁcial 1 g onboard environment.
Sci Rep. 2021 Apr 28;11(1):9168. doi: 10.1038/s41598-021-88392-4.
3. Nakamagoe K, Yamada S, Kawakami R, Maeno T, Koganezawa T, Tamaoka A: ClinicalApplication of the Vestibular Stimulation Effect on Balance Disorders with Dementia. Curr
Alzheimer Res. 2021 Mar 23. doi: 10.2174/1567205018666210324105642.
4. Hayashida A, Li Y, Yoshino H, Daida K, Ikeda A, Ogaki K, Fuse A, Mori A, Takanashi M,
Nakahara T, Yoritaka A, Tomizawa Y, Furukawa Y, Kanai K, Nakayama Y, Ito H, Ogino M,
Hattori Y,… Nakamagoe K, Tamaoka A. Hattori N.: The identified clinical features ofParkinsonʼs disease in homo-, heterozygous and digenic variants of PINK1. Neurobiologyof Aging. 2021 Jan;97:146.e1146.e13. doi: 10.1016/j.neurobiolaging.2020.06.017.
5. Shiraishi H, Yamada K, Egawa K, Ishige M, Ochi F, Watanabe A, Kawakami S, Kuzume
K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Kobayashi
K, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N: Eﬃcacy of bezaﬁbrate forpreventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase
deﬁciency. Brain Dev. 2021 Feb;43(2):214-219. doi: 10.1016/j.braindev.2020.07.019.
6. Naruse H, Ishiura H, Mitsui J, Takahashi Y, Matsukawa T, Sakuishi K, Nakamagoe K,
Miyake Z, Tamaoka A, Goto J, Yoshimura J, Doi K, Morishita S, Toda T, Tsuji S: Splice-site
mutations in KIF5A in the Japanese case series of amyotrophic lateral sclerosis.
Neurogenetics. 2020 Aug 19. doi: 10.1007/s10048-020-00626-1.
7.

Shiraiwa N, Hoshino S, Saito G, Tamaoka A, Ohkoshi N: Clinical features ofhemichoreahemiballism: A stroke-related movement disorder, 2020, Neurol Int, 12(8328): 68
8. Ishii A, Okada H, Hayashita-Kinoh H, Shin JH, Tamaoka A, Okada T, Takeda S: rAAV8
and rAAV9- Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in NonHuman

Primates

Mol

Ther

Methods

Clin

Dev.

2020

May

22;

18:

44-49.

doi:10.1016/j.omtm.2020.05.012. eCollection 2020 Sep 11.PMID: 32577431, 2020
9.

Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, Nishida H, Komori

T, Seki M, Komatsu T, Nakamagoe K, Ikeda T, Yoshida M, Takahashi T, Ono H, Nishiyama
S, Kuroda H, Nakashima I, Suzuki H, Bradl M, Lassmann H, Fujihara K, Aoki M: Japan MOGantibody Disease Consortium (including Tamaoka A)Myelin oligodendrocyte glycoprotein
antibody-associated disease: an immunopathological study Brain. 2020 May 1; 143(5): 14311446. doi:10.1093/brain/awaa102, 2020
10.

Koshi-Mano K, Mano T, Morishima M, Murayama S, Tamaoka A, Tsuji S, Toda T,

Iwata A: Neuron- speciﬁc analysis of histone modiﬁcations with post-mortem brains

Sci

Rep. 2020 Feb 28; 10(1):3767. doi:10.1038/s41598-020-60775-z., 2020
11. Aizawa S, Okada T, Keino-Masu K, Doan TH, Koganezawa T, Akiyama M, Tamaoka A,
Masu M: Abnormal Pyramidal Decussation and Bilateral Projection of the Corticospinal Tract
Axons in Mice Lacking the Heparan Sulfate Endosulfatases, Sulf1 and Sulf2 Front Mol
Neurosci. 2020 Jan 21; 12:333. doi:10.3389/fnmol.2019.00333. eCollection 2019, 2020
12. Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M, Rovatirelin Study Group:
Eﬀect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebocontrolled phase 3 trials J Neurol Neurosurg Psychiatry. 2020 Jan 14. pii: jnnp-2019-322168.
doi:10.1136/jnnp-2019- 322168. [Epub ahead of print], 2020
13. Takeuchi A, Mohri S, Kai H, Tamaoka A, Kobayashi A, Mizusawa H, Iwasaki Y, Yoshida
M, Shimizu H, Murayama S, Kuroda S, Morita M, Parchi P, Kitamoto T.: Two distinct prionsin fatal familial insomnia and its sporadic form. Brain Commun. 2019 Dec 9;1(1):fcz045. doi:
10.1093/braincomms/ fcz045. eCollection 2019.
14. Nohara S, Ishii A, Yamamoto F, Yanagiha K, Moriyama T, Tozaka N, Miyake Z, Yatsuga
S, Koga Y, Hosaka T, Terada M, Yamaguchi T, Aizawa S, Mamada N, Tsuji H, Tomidokoro
Y, Nakamagoe K, Ishii K, Watanabe M, Tamaoka A: GDF-15, a mitochondrial diseasebiomarker, is associated with the severity of multiple sclerosis J Neurol Sci. 2019 Oct 15; 405:
116429. doi:10.1016/ j.jns.2019.116429. Epub 2019 Aug 22., 201915. Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe
A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina
N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N: Open-label
clinical trial of bezaﬁbrate treatment in patients with fatty acid oxidation disorders in Japan;
2nd report QOL survey

Mol Genet Metab Rep. 2019 Jul 25; 20: 100496.

doi:10.1016/j.ymgmr.2019.100496. eCollection 2019 Sep., 2019
16. Tomono T, Hirai Y, Chono H, Mineno J, Ishii A, Onodera M, Tamaoka A, Okada T:

Infectivity assessment of recombinant adeno-associated virus (rAAV) and wild-type AAV(wtAAV) exposed to various diluents and environmental conditions Hum Gene Ther Methods.
2019 Jul 18. doi:10.1089/ hgtb.2019.082. [Epub ahead of print], 201917. Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, Yamada M: Nationwide
survey on cerebral amyloid angiopathy in Japan Eur J Neurol. 2019 Jun 24.
doi:10.1111/ene.14031. [Epub ahead of print], 201918. Ishii K, Nemoto K, Iwasaki N, Takeda T, Masuda T, Shibata Y, Tamaoka A: Decreased
regional cerebral blood ﬂow in patients with diphenylarsinic acid intoxication Eur J Neurol.
2019 Jan; 26(1): 136-141. doi:10.1111/ene.13783. Epub 2018 Sep 19.PMID: 30133051, 201919. Taniguchi K, Yamamoto F, Arai T, Yang J, Sakai Y, Itoh M, Mamada N, Sekiguchi M,
Yamada D, Saitoh A, Kametani F, Tamaoka A, Araki YM, Wada K, Mizusawa H, Araki W:
Tyrosol Reduces Amyloid-β Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, andCognitive Disturbances in Alzheimerʼs Disease Model Mice J Alzheimers Dis. 2019 Jun 21.
doi:10.3233/JAD-190098. [Epub ahead of print]PMID: 31227651, 201920. Nakamagoe K, Yamada S, Kawakami R, Koganezawa T, Tamaoka A: Abnormal Saccadic
Intrusions with Alzheimerʼs Disease in Darkness Curr Alzheimer Res. 2019 Mar 10.
doi:10.2174/1567205016 666190311102130. [Epub ahead of print], 201921.

Nakamagoe K, Yamada S, Kawakami R, Miyake Z, Tozaka N, Okune S, Takeda H,

Koganezawa T, Tamaoka A: Vestibular Dysfunction as Cortical Damage With Amyotrophic
Lateral Sclerosis J Neurol Sci 2019 Feb 15; 397: 4-8. doi:10.1016/j.jns.2018.12.006. Epub
2018 Dec 5, 201922. Yamamoto F, Taniguchi K, Mamada N, Tamaoka A, Kametani F, Lakshmana MK, Araki
W: TFEB- mediated enhancement of the autophagy-lysosomal pathway dually modulates theprocess of amyloid β-protein generation in neurons Neuroscience. 2019 Jan 21. pii: S03064522(19)30030-2. doi:10.1016/j.neuroscience.2019.01.010. [Epub ahead of print], 201923. Yamada E, Ishikawa E, Watanabe R, Matsumura H, Sakamoto N, Ishii A, Tamaoka A,
Hattori K, Obara N, Chiba S, Nakamagoe K, Matsuda M, Tsurubuchi T, Tomidokoro Y,
Akutsu H, Zaboronok A, Shibuya M, Takano S, Matsumura A: Random Skin Biopsies Before
Brain Biopsy for Intravascular Large B-Cell Lymphoma World Neurosurg. 2019 Jan; 121:e364-e369. doi:10.1016/ j.wneu.2018.09.110. Epub 2018 Sep 25, 201924.

Cousyn L, Law-Ye B, Pyatigorskaya N, Debs R, Froissart R, Piraud M, Federico A,

Salvatore S, Cerase A, Macário MC, Durães J, Kim SH, Adachi H, Audoin B, Ayrignac X, Da
Y, Henderson R, La Piana R, Laule C, Nakamagoe K, Raininko R, Schols L, Sirrs SM, Viader
F, Jastrzbski K, Leclercq D, Nadjar Y. Brain: MRI features and scoring of leukodystrophy inadult-onset

Krabbedisease.

Neurology.

2019

Aug

13;

doi:10.1212/WNL.0000000000007943. Epub 2019 Jul 23. (2019 年度)

93(7):

e647-e652.

25.

Shiraiwa N, Tamaoka A, Ohkoshi N: Clinical features of drug-induced Parkinsonism

Neurol Int. 2018 Dec 20; 10(4): 7877. doi:10.4081/ni.2018.7877. eCollection 2018 Dec 5.,
2018
26. Tomono T, Hirai Y, Okada H, Miyagawa Y, Adachi K, Sakamoto S, Kawano Y, Chono
H, Mineno J, Ishii A, Shimada T, Onodera M, Tamaoka A, Okada T: Highly Eﬃcient
Ultracentrifugation-free Chromatographic Puriﬁcation of Recombinant AAV Serotype 9 Mol
Ther Methods Clin Dev. 2018 Nov 1; 11: 180-190. doi:10.1016/j.omtm.2018.10.015.
eCollection 2018 Dec 14.PMID: 30533449, 201827.

Hosaka T, Yamashita T, Teramoto S, Hirose N, Tamaoka A, Kwak S: ADAR2-

dependent A-to-IRNA editing in the extracellular linear and circular RNAs

Neurosci Res.

2018 Nov 16. pii: S0168- 0102(18)30587-X. doi:10.1016/j.neures.2018.11.005. [Epub aheadof print]PMID: 30448461, 2018
28. Terada M, Suzuki G, Nonaka T, Kametani F, Tamaoka A, Hasegawa M: The eﬀect oftruncation on prion-like properties of α-synuclein J Biol Chem. 2018 Jul 20. pii:
jbc.RA118.001862. doi:10.1074/ jbc.RA118.001862. [Epub ahead of print], 201829.

Masuda T, Ishii K, Morishita Y, Iwasaki N, Shibata Y, Tamaoka A: Hepatic

histopathological changes and dysfunction in primates following exposure to organic arsenic
diphenylarsinic acid J Toxicol Sci. 2018; 43(5): 291-298. doi:10.2131/jts.43.291, 2018
30. Kuwabara S, Misawa S, Mori M, Iwai Y, Ochi K, Suzuki H, Nodera H, Tamaoka A, Iijima
M, Toda T, Yoshikawa H, Kanda T, Sakamoto K, Kusunoki S, Sobue G, Kaji R, Glovenin-I
MMN Study Group: Intravenous immunoglobulin for maintenance treatment of multifocal
motor neuropathy: A multi- center, open-label, 52-week phase 3 trial J Peripher Nerv Syst.
2018 Apr 10. doi:10.1111/jns.12268. [Epub ahead of print], 201831. Yamada K, Shiraishi H, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe
A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina
N, Yokoshiki S, Miyakoshi T, Ono K, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N: Openlabel clinical trial of bezaﬁbrate treatment in patients with fatty acid oxidation disorders inJapan Mol Genet Metab Rep. 2018 Feb 22; 15: 55-63. doi:10.1016/j.ymgmr.2018.02.003.
eCollection 2018 Jun.,2018
32. Ishiura H, Doi K, Mitsui J, Yoshimura J, Matsukawa MK, Fujiyama A, Toyoshima Y,
Kakita A, Takahashi H, Suzuki Y, Sugano S, Qu W, Ichikawa K, Yurino H, Higasa K, Shibata
S, Mitsue A, Tanaka M, Ichikawa Y, Takahashi Y, Date H, Matsukawa T, Kanda J, Nakamoto
FK, Higashihara M, Abe K, Koike R, Sasagawa M, Kuroha Y, Hasegawa N, Kanesawa N,
Kondo T, Hitomi T, Tada M, Takano H, Saito Y, Sanpei K, Onodera O, Nishizawa M,
Nakamura M, Yasuda T, Sakiyama Y, Otsuka M, Ueki A, Kaida KI, Shimizu J, Hanajima R,

Hayashi T, Terao Y, Inomata-Terada S, Hamada M, Shirota Y, Kubota A, Ugawa Y, Koh K,
Takiyama Y, Ohsawa-Yoshida N, Ishiura S, Yamasaki R, Tamaoka A, Akiyama H, Otsuki T,
Sano A, Ikeda A, Goto J, Morishita S, Tsuji S: Expansions of intronic TTTCA and TTTTA
repeats in benign adult familial myoclonic epilepsy Nat Genet. 2018 Mar 5.
doi:10.1038/s41588-018-0067-2. [Epub ahead of print], 201833. Masuda T, Ishii K, Nakayama T, Iwasaki N, Shibata Y, Tamaoka A: High-sensitivity
quantitative analysis reveals the non-linear relationship between the dose and deposition ofdiphenylarsinic acid in the rat central nervous system following its subchronic exposure
Neurotoxicol Teratol. 2018 Jan - Feb; 65: 26-33. doi:10.1016/j.ntt.2017.12.004. Epub 2017
Dec 7, 201834.

Nakamagoe K, Tozaka N, Nohara S, Kawakami R, Yamada S, Koganezawa T,

Tamaoka A: Upbeat nystagmus is a useful sign in the regional diagnosis of trigeminal nerve
disorder with multiple sclerosis
Mult Scler Relat Disord. 2018 Jan; 19: 59-61. doi:10.1016/j.msard.2017.11.008. Epub 2017
Nov 9.,
2018
35. Mano T, Nagata K, Nonaka T, Tarutani A, Imamura T, Hashimoto T, Bannai T, KoshiMano K, Tsuchida T, Ohtomo R, Takahashi-Fujigasaki J, Yamashita S, Ohyagi Y, Yamasaki
R, Tsuji S, Tamaoka A, Ikeuchi T, Saido TC, Iwatsubo T, Ushijima T, Murayama S, Hasegawa
M, Iwata A: Neuron-specific methylome analysis reveals epigenetic regulation and tau-related
dysfunction of BRCA1 in Alzheimerʼs disease .Proc Natl Acad Sci U S A. 2017 Nov 7; 114(45):E9645-E9654. doi:10.1073/pnas.1707151114. Epub 2017 Oct 17, 201736. Naruse H, Ishiura H, Mitsui J, Date H, Takahashi Y, Matsukawa T, Tanaka M, Ishii A,
Tamaoka A, Hokkoku K, Sonoo M, Segawa M, Ugawa Y, Doi K, Yoshimura J, Morishita S,
Goto J, Tsuji S: Molecular epidemiological study of familial amyotrophic lateral sclerosis inJapanese population by whole-exome sequencing and identiﬁcation of novel HNRNPA1
mutation

Neurobiol

Aging.

2017

Sep

6.

pii:

S0197-4580(17)30286-5.

doi:10.1016/j.neurobiolaging.2017.08.030. [Epub ahead of print], 201737. Boonruamkaew P, Chonpathompikunlert P, Vong LB, Sakaue S, Tomidokoro Y, Ishii K,
Tamaoka A, Nagasaki Y: Chronic treatment with a smart antioxidative nanoparticle forinhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimerʼs disease Sci
Rep. 2017 Jun 19; 7(1):3785. doi:10.1038/s41598-017-03411-7, 2017
38. Wu T, Ido K, Osada Y, Kotani S, Tamaoka A, Hanada T: The neuroprotective eﬀect ofperampanel in lithium-pilocarpine rat seizure model Epilepsy Res. 2017 Jun 14. pii: S09201211(17)30118-3. doi:10.1016/j.eplepsyres.2017.06.002. [Epub ahead of print], 2017

39. Shimada S, Arai T, Tamaoka A, Homma M: Liquorice-induced hypokalaemia in patientstreated with Yokukansan preparations: identification of the risk factors in a retrospective
cohort study BMJ Open. 2017 Jun 15; 7(6): e014218. doi:10.1136/bmjopen-2016-014218,
2017
40. Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo
T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T,
Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo
H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi
R, Yamanaka S, Inoue H: The Src/c-Abl pathway is a potential therapeutic target inamyotrophic lateral sclerosis Sci Transl Med. 2017 May 24; 9(391). pii: eaaf3962.
doi:10.1126/scitranslmed.aaf3962, 201741. Mamada N, Tanokashira D, Ishii K, Tamaoka A, Araki W: Mitochondria are devoid ofamyloid β-protein (Aβ)-producing secretases: Evidence for unlikely occurrence within
mitochondria of Aβ generation from amyloid precursor protein Biochem Biophys Res
Commun. 2017 Apr 29; 486(2): 321-328. doi:10.1016/j.bbrc.2017.03.035. Epub 2017 Mar
14.PMID: 28302486, 2017
42. Tanokashira D, Mamada N, Yamamoto F, Taniguchi K, Tamaoka A, Lakshmana MK,
Araki W: The neurotoxicity of amyloid β-protein oligomers is reversible in a primary neuronmodel Mol Brain. 2017 Jan 31; 10(1): 4. doi:10.1186/s13041-016-0284-5., 201743.

Masuda T, Ishii K, Seto Y, Hosoya T, Tanaka R, Nakayama T, Iwasaki N, Shibata Y,

Tamaoka A: Long-term accumulation of diphenylarsinic acid in the central nervous system ofcynomolgus monkeys

Arch Toxicol. 2017 Aug; 91(8): 2799-2812, 201744. Masuda T, Itoh J, Koide T, Tomidokoro Y, Takei Y, Ishii K, Tamaoka A: Transforming
growth factor-β1 in the cerebrospinal fluid of patients with distinct neurodegenerative
diseases J Clin Neurosci. 2017 Jan; 35: 47-49, 201745. Ishii, A.; Yatsuga, S.; Koga, Y.; Tamaoka, A.: GDF-15 expression in mitochondrial andotherneurological diseases

NEUROMUSCULAR DISORDERS 27(2): S119-S120,

2017/10/01
46.

Nakamagoe K, Kadono K, Koganezawa T, Takiguchi M, Terada M, Yamamoto F,

Moriyama T, Yanagiha K, Nohara S, Tozaka N, Miyake Z, Aizawa S, Furusho K, Tamaoka A:
Vestibular Impairment in Frontotemporal Dementia Syndrome Dement Geriatr Cogn Dis
Extra. 2016 May 26; 6(2): 194-204, 2016
47. Oikawa T, Nonaka T, Terada M, Tamaoka A, Hisanaga S, Hasegawa M: α-Synucleinﬁbrils exhibit gain of toxic function, promoting tau aggregateon and inhibiting microtubule
assembly J Biol Chem 2016; 291(29): 15046-56, 2016
48. Tomono T, Hirai Y, Okada H, Adachi K, Ishii A, Shimada T, Onodera M, Tamaoka A,

Okada T: Ultracentrifugation-free chromatography-mediated large-scale purification ofrecombinant adeno- associated virus serotype 1 (rAAV1) Mol Ther Methods Clin Dev. 2016
Feb 10; 3: 15058. doi:10.1038/mtm.2015.58. eCollection 2016.PMID: 26913289, 201649.

Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R, The

Zonisamide PD Study Group: Randomized placebo-controlled trial of zonisamide in patientswith Parkinsonʼs disease Neurology and Clinical Neuroscience 4(2016): 10-15, 2016
50. Rosen RF, Tomidokoro Y, Farberg AS, Dooyema J, Ciliax B, Preuss TM, Neubert TA,
Ghiso JA, LeVine H 3rd, Walker LC.: Comparative pathobiology of β-amyloid and the uniquesusceptibilityof humans to Alzheimerʼs disease. Neurobiol Aging. 44: 185-196, 201651.

Yatsuga, Shuichi; Ishii, Akiko; Kitamura, Miyuki; Koga, Yasutoshi: Serum GDF15

levels in diseaseswith similarity to mitochondrialdisorders

MITOCHONDRION 31 93,

2016/11/01
52. Ishii, A., Yoshida, M., Ueno, H., Kokubo, K., Ohkoshi, N., Tamaoka, A.: Antioxidants
improve muscledegeneration process NEUROMUSCULARDISORDERS 26 2 S204
10.1016/ j.nmd.2016.06.428, 2016/10/01
53. Yamada K, Kobayashi H, Bo R, Takahashi T, Purevsuren J, Hasegawa Y, Taketani T,
Fukuda S, Ohkubo T, Yokota T, Watanabe M, Tsunemi T, Mizusawa H, Takuma H, Shioya
A, Ishii A, Tamaoka A, Shigematsu Y, Sugie H, Yamaguchi S: Clinical, biochemical andmolecular investigation of adult- onset glutaric acidemia type II: Characteristics incomparison

withpediatric

cases

Brain

Dev.

2016

Mar;

38(3):

293-301.

doi:10.1016/j.braindev.2015.08.011. Epub 2015 Sep 26, 2015
54. Nomoto M, Kubo S, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, Hattori N, PD Study
Group: A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: arepeat dose and pharmacyetic study Clin Neuropharmacol 2015; 38(6): 241-7, 2015
55. Mamada N, Tanokashira D, Hosaka A, Kametani F, Tamaoka A, Araki W: Amyloid βproteinoligomers upregulate the β-secretase, BACE1, through a post-translational
mechanism involving its altered subcellular distribution in neurons Mol Brain. 2015 Nov 9;8(1): 73. doi:10.1186/s13041- 015-0163-5.PMID: 26552445, 2015
56. Tanokashira D, Motoki K, Minegishi S, Hosaka A, Mamada N, Tamaoka A, Okada T,
Lakshmana MK, Araki W: LRP1 Downregulates the Alzheimerʼs β-Secretase BACE1 by
Modulating Its Intraneuronal Trafficking(1, 2, 3) eNeuro. 2015 Apr 22; 2(2). pii:
ENEURO.0006-15.2015. doi:10.1523/ENEURO.0006-15.2015. eCollection 2015 MarApr.PMID: 26464978, 2015
57. Nakamagoe K, Fujimiya S, Koganezawa T, Kadono K, Shimizu K, Fujizuka N, Takiguchi
S, Ueno T, Monzen T, Tamaoka A: Vestibular Function Impairment in Alzheimerʼs Disease
J Alzheimers Dis. 2015 Jul 9; 47(1): 185-96. doi:10.3233/JAD-142646.PMID: 2640276, 2015

58. Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, Japan Zonisamide
on PD Study Group: Zonisamide improves wearing-oﬀ in Parkinsonʼs disease: A randomized,
double-blind study Mov Disord. 2015 Sep; 30(10): 1343-50. doi:10.1002/mds.26286. Epub2015 Jun 12.PMID: 26094993, 201559. Satoh JI, Kino Y, Motohashi N, Ishida T, Yagishita S, Jinnai K, Arai N, Nakamagoe K,
Tamaoka A, Saito Y, Arima K: Immunohistochemical characterization of CD33 expression on
microglia in Nasu- Hakola disease brains Neuropathology. 2015 Dec; 35(6): 529-37.
doi:10.1111/neup.12222. Epub 2015 Jun 18.PMID: 26087043, 2015
60.

Kondo T, Mizuno Y, Japanese Istradefylline Study Group: A long-term study of

istradefylline safety and eﬃcacy in patients with Parkinson disease Clin Neuropharmacol.
2015 Mar-Apr; 38(2): 41-6. doi:10.1097/WNF.0000000000000073.PMID: 25768849, 2015
61.

Hatsuta H, Takao M, Ishii K, Ishiwata K, Saito Y, Kanemaru K, Arai T, Suhara T,

Shimada H, Shinotoh H, Tamaoka A, Murayama S: Amyloid β Accumulation Assessed with
11C-Pittsburgh Compound B PET and Postmortem Neuropathology Curr Alzheimer Res.
2015; 12(3): 278-86.Mar 2. [Epub ahead of print]PMID: 25731622, 201562. Shioya A, Saito Y, Arima K, Kakuta Y, Yuzuriha T, Tanaka N, Murayama S, Tamaoka A:
Neurodegenerative changes in patients with clinical history of bipolar disorders
Neuropathology. 2015 Jun; 35(3): 245-53. doi:10.1111/neup.12191. Epub 2015 Mar
30.PMID: 25819679, 2015
63. Takao T, Tanaka N, Iizuka N, Saitou H, Tamaoka A, Yanagi H: Improvement of gait
ability with a short-term intensive gait rehabilitation program using body weight support
treadmill training in community dwelling chronic poststroke survivors J Phys Ther Sci. 2015
Jan; 27(1): 159-63. doi:10.1589/jpts.27.159. Epub 2015 Jan 9.PMID: 25642063 [PubMed],2015
64. Osaki Y, Nakagawa Y, Miyahara S, Iwasaki H, Ishii A, Matsuzaka T, Kobayashi K, Yatoh
S, Takahashi A, Yahagi N, Suzuki H, Sone H, Ohashi K, Ishibashi S, Yamada N, Shimano H.:
Skeletalmuscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A
model forstatin-induced myopathy. Biochem Biophys Res Commun 466(3): 536-540, 2015
65.

Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T, Ito M,

Tanaka M, Saiki R, Koga Y.: Growth diﬀerentiation factor 15 as a useful biomarker for
mitochondrial disorders. Ann Neurol 78(5): 814-823, 201566. Satoh J, Motohashi N, Kino Y, Ishida T, Yagishita S, Jinnai K, Arai N, Nakamagoe K,
Tamaoka A, Saito Y, Arima K: LC3, an autophagosome marker, is expressed onoligodendrocytes in Nasu- Hakola disease brains Orphanet J Rare Dis. 2014 May 1; 9: 68.
doi:10.1186/1750-1172-9-68.PMID: 24886140 [PubMed - in process], 2014
67. Hattori N, Nomoto M, 6500-004 Study Group: Sustained efficacy of apomorphine inJapanese patients with advanced Parkinsonʼs disease Parkinsonism Relat Disord. 2014 Aug;20(8): 819-23. doi:10.1016/j.parkreldis.2014.04.008. Epub 2014 Apr 18.PMID: 24792991,
2014
68. Ishii K, Itoh Y, Iwasaki N, Shibata Y, Tamaoka A: Detection of diphenylarsinic acid andits derivatives in human serum and cerebrospinal fluid Clin Chim Acta. 2014 Apr 20; 431:
227-31. doi:10.1016/j.cca.2014.01.029. Epub 2014 Feb 6.PMID: 24508991 [PubMed - inprocess]Related citationsSelect item 24492697, 2014
69. Araki W, Minegishi S, Motoki K, Kume H, Hohjoh H, Araki YM, Tamaoka A: DiseaseAssociated Mutations of TDP-43 Promote Turnover of the Protein Through the Proteasomal
Pathway Mol Neurobiol. 2014 Jan 30. [Epub ahead of print]PMID: 24477737 [PubMed - assupplied by publisher] Related citations, 201470. Hosokawa M, Arai T, Yamashita M, Tsuji H, Nonaka T, Masuda-Suzukake M, Tamaoka
A, Hasegawa M, Akiyama H: Diﬀerential diagnosis of amyotrophic lateral sclerosis from
Guillain-Barré syndrome by quantitative determination of TDP-43 in cerebrospinal ﬂuid Int
J Neurosci. 2014; 124(5): 344- 349, 2014
71. Hoshino S, Sakamoto K, Vassilopoulos S, Camus SM, Griffin CA, Esk C, Torres JA,
Ohkoshi N, Ishii A, Tamaoka A, Funke BH, Kucherlapati R, Margeta M, Rando TA, Brodsky
FM: The CHC22 clathrin-GLUT4 transport pathway contributes to skeletal muscle
regeneration PLoS One. 2013 Oct 30; 8(10): e77787. doi:10.1371/journal.pone.0077787.
eCollection 2013, 2013
72. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, Tamaoka A, Murayama
S, Saido T, Tsuji S: Altered CpG methylation in sporadic Alzheimerʼs disease is associatedwith APP and MAPT dysregulation Hum Mol Genet. 2013 Oct 6. [Epub ahead of print] 2014
Feb 1; 23(3): 648-56. doi:10.1093/hmg/ddt451. Epub 2013 Sep 18.PMID: 24101602[PubMed - indexed for MEDLINE], 2013
73. Akamatsu M, Takuma H, Yamashita T, Okada T, Keino-Masu K, Ishii K, Kwak S, Masu
M, Tamaoka A: A unique mouse model for investigating the properties of amyotrophic lateralsclerosis-associated protein TDP-43, by in utero electroporation Neurosci Res. 2013; 77(4):234-241.2013 Sep 27. doi:pii: S0168-0102(13)00206-X. 10.1016/j.neures.2013.09.009.
[Epub ahead of print], 2013
74. Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo
T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H,
Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto
K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M,
Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H: Response toComment on “Drug Screening for ALS Using Patient-Speciﬁc Induced Pluripotent StemCells” Sci Transl Med. 2013 Jun 5; 5(188): 188lr2. doi:10.1126/scitranslmed.3005697, 201375. Hosaka A, Araki W, Oda A, Tomidokoro Y, Tamaoka A: Statins reduce amyloid βpeptide production by modulating amyloid precursor protein maturation and phosphorylation
through a cholesterol- independent mechanism in cultured neurons Neurochem Res, 38: 589600, 2013. Doi: 10.1007/ s11064-012-0956-1, 2013
76. Araki W, Oda A, Motoki K, Hattori K, Itoh M, Yuasa S, Konishi Y, Shin RW, Tamaoka
A, Ogino K: Reduction of β-amyloid accumulation by reticulon 3 in transgenic mice Curr
Alzheimer Res. 2013 Feb; 10(2): 135-42., 2013
77. Nakamagoe K, Fujizuka N, Koganezawa T, Shimizu K, Takiguchi S, Horaguchi T, Ishii
K, Tamaoka A: Residual central nervous system damage due to organoarsenic poisoning
Neurotoxicol Teratol. 2013 May-Jun; 37: 33-8. doi:10.1016/j.ntt.2013.02.007. Epub 2013
Feb 21., 2013
78. Ichikawa Y, Ishiura H, Mitsui J, Takahashi Y, Kobayashi S, Takuma H, Kanazawa I, Doi
K, Yoshimura J, Morishita S, Goto J, Tsuji S.: Exome analysis reveals a Japanese family
withspinocerebellar ataxia, autosomal recessive 1. J Neurol Sci 331(1-2): 158-160, 2013
79.

Ishii A, Ohkoshi N, Yoshida M, Tamaoka A.: The effect of water-soluble fullerene

withdifferentnumber of hydroxyl groups in muscle regeneration process of experimantal
murine skeletalmuscle. Neuromuscular Disorders 23(9-10): 838, 201380.

Umeda T, Yamashita T, Kimura T, Ohnishi K, Takuma H, Ozeki T, Takashima A,

Tomiyama T, Mori H.: Neurodegenerative disorder FTDP-17-related tau intron 10 +16C -> T mutation increasestau exon 10 splicing and causes tauopathy in transgenic mice. Am J
Pathol 183(1): 211-225, 2013
81. Hosaka A, Araki W, Oda A, Tomidokoro Y, Tamaoka A.: Statins reduce amyloid βpeptideproduction by modulating amyloid precursor protein maturation and phosphorylation
through acholesterol- independent mechanism in cultured neurons.

Neurochem Res

doi:10.1007/s11064-012-0956-1.,
2012
82.

Watanabe M, Tamaoka A, Morishita Y, Noguchi M: Cilnidipine lowers plasma leptinof patients with obese hypertension associated with cerebrovascular disorder

Open Access

Scientiﬁc Reports 1: 529,
2012.Doi: 10.4172/scientiﬁcreports.529 Journal of Hypertension: Open Access Volume 1・
Issue 11・2012
83.

Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M, Hosokawa M,

Yoshida M, Hatsuta H, Takao M, Saito Y, Murayama S, Akiyama H, Hasegawa M, Mann DM,
Tamaoka A: Molecular analysis and biochemical classification of TDP-43 proteinopathy Brain.

2012 Nov; 135(Pt 11): 3380-91. doi:10.1093/brain/aws230. Epub 2012 Oct 3, 201284.

Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F,

Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki
T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K,
Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A,
Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H: Drug
Screening for ALS Using Patient-Speciﬁc Induced Pluripotent Stem Cells Sci Transl Med.
2012 Aug 1; 4(145): 145ra104., 2012
85. Motoki K, Kume H, Oda A, Tamaoka A, Hosaka A, Kametani F, Araki W: Neuronal βamyloid generation is independent of lipid raft association of β-secretase BACE1: analysis
with a palmitoylation-deﬁcient mutant Brain Behav. 2012 May; 2(3): 270-82, 2012
86. Tanaka N, Saitou H, Takao T, Iizuka N, Okuno J, Yano H, Tamaoka A, Yanagi H: Effectsof gait rehabilitation with a footpad-type locomotion interface in patients with chronic poststroke

hemiparesis:

a

pilot

study

Clin

Rehabil.

2012

Aug;

26(8):

686-95.

doi:10.1177/0269215511432356. Epub 2012 Jan 24, 2012
87. Tsuji H, Nonaka T, Yamashita M, Masuda-Suzukake M, Kametani F, Akiyama H, Mann
DM, Tamaoka A, Hasegawa M: Epitope mapping of antibodies against TDP-43 and detectionof protease- resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis andfrontotemporal lobar degeneration Biochem Biophys Res Commun. 2012 Jan 6; 417(1): 11621., 2012
88.

Ishii A, Ohkoshi N, Tamaoka A.: The eﬀect of water-soluble fullerene in muscle

regenerationprocess of experimantal murine skeletal muscle.

Neuromuscular Disorders

22: 905-906, 2012
89.

Ishii A, Okada H, Hayashita-Kinou H, Okada T, Takeda S.: rAAV8/9-mediatedmuscle transduction with tacrolimus in non-human primate.

Molecular Therapy 20: 203-

204, 2012
90. Nakano-Yokomizo Y, Tahara-Hanaoka-S, Nakahashi-Oda C, Nabekura T, Tchao NK,
Kadosaki M, Totsuka N, Kurita N, Nakamagoe K, Tamaoka A, Takai T, Yasui T, Kikutani H,
Hosoda S, Shibuya K, Lanier LL, Shibuya A: The immunoreceptor adaptor protein DAP12
suppression B lymphocyte- driven adaptive immune responses J Exp Med. 2011; 208(8):1661-71, 201191. Hasegawa M, Nonaka T, Tsuji H, Tamaoka A, Yamashita M, Kametani F, Yoshida M,
Arai T, Akiyama H: Molecular Dissection of TDP-43 Proteinopathies J Mol Neurosci. 2011:45(3): 480-5. Jun 16. [Epub ahead of print], 2011
92.

Watanabe M, Takeda T, Nakamagoe K, Tamaoka A: Sequential imaging analysis using

MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve inParkinsonʼs disease Eur J Neurol. 2011 Jul; 18(7): 1010-3. doi:10.1111/j.14681331.2010.03211.x. Epub 201093.

Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A: CpG

demethylation enhances alpha-synuclein expression and aﬀects the pathogenesis of
Parkinsonʼs disease PLoS One. 2010 Nov 24; 5(11): e15522, 2010
94. Tomidokoro Y, Tamaoka A, Holton JL, Lashley T, Frangione B, Revesz T, Rostagno A,
Ghiso J: PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI
MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE
CENTRAL NERVOUS SYSTEM Hirosaki Igaku. 2010 Jul 8; 61(Suppl): S262-S269, 201095.

Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N,

Tamaoka A, Nakagawa M, El-Agnaf OM: Detection of elevated levels of alpha-synuclein
oligomers in CSF from patients with Parkinson disease

Neurology. 2010 Oct 20. [Epubahead of print], 2010
96.

Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline

Study Group: Clinical eﬃcacy of istradefylline (KW-6002) in Parkinsonʼs disease: arandomized, controlled study Mov Disord. 2010; 25(10): 1437-43, 2010
97.

Araki W, Kametani F, Oda A, Tamaoka A: MEK inhibitors suppress beta-amyloid

production by altering the level of a beta-C-terminal fragment of amyloid precursor protein
in neuronal cells FEBS Lett. 2010; 584(15): 3410-4, 201098. Hirohata M, Yoshita M, Ishida C, Ikeda S-I, Tamaoka A, Kuzuhara S, Shoji M, Ando Y,
Tokuda T, Yamada M: Clinical features of non-hypertensive lobar intracerebral hemorrhage
related to cerebral amyloid angiopathy European J of Neurology 17(6): 823-829, 201099.

Oda A, Tamaoka A, Araki W: Oxidative stress up-regulates presenilin 1 in lipid rafts

in neuronal cells J Neurosci Res. 2010; 85(5): 1137-45, 2010100.

Saitoh Y, Ogawa M, Naito Y, Komatsuzaki Y, Tagaya H, Arima K, Tamaoka A,

Kitamoto T, Murata M: Discordant clinicopathological phenotypes in a Japanese kindred of
fatal familial insomnia Neurology 74(1): 86-89, 2010
101. Suzuki T, Murakami K, Izuo N, Kume T, Akaike A, Nagata T, Nishizaki T, Tomiyama
T, Takuma H, Mori H, Irie K: E22Δ Mutation in Amyloid β-Protein Promotes β-Sheet
Transformation, Radical Production, and Synaptotoxicity, But Not Neurotoxicity.
International Journal of Alzheimers Disease: 431320, 2011
102. Ishii A, Shioya A, Hosaka A, Ohkoshi N, Nakamagoe K, Tamaoka A: Clinical experience
with L-arginine treatment in MELAS syndrome; good response in young butnot in adultonset patients. Acta Myologica XXIX: 236, 2010
103. Ishii A, Shioya A, Hosaka A, Ohkoshi N, Nakamagoe K, Tamaoka A: Clinical experience
with L-arginine treatment in MELAS.Neuromuscular Disorders 20: 678, 2010

104. Hosaka A, Ishii A, Tomidokoro Y, Tsuji H, Oda A, Takuma H, Ishii K, Tamaoka A:
Clinical and imaging features of inclusion body myositis.

Neuromuscular Disorders 20:

631, 2010
105.

Shioya A, Takuma H, Ishii A, Tamaoka A: A polymyositis patient with anti-signal

recognition particle(SRP) antibody refractory tocorticosteroid treatment.

Neuromuscular Disorders 20: 633,

2010
106. Nakamagoe K, Ishii K, Watanabe M, Tamaoka A: A pontomedullary lesion of aberrant
pyramidal tract with ipsilateral central facial paresis.BMJ Case Reports. BMJ Case Reports
published online December 3, 2010doi:10.1136/bcr05, 303, 2010107.

Nakamagoe K, Hosaka A, Kondo Y, Ishikawa E, Tamaoka A: A case of idiopathic

hypertrophic cranial pachymeningitis presenting high values of matrixmetalloproteinase. BMJ
Case Reports. BMJ Case Reports published online February 25, 2010doi:10.1136/bcr, 06,
2009
108.

Nakamagoe K, Ishii K, Tamaoka A: Vertical nystagmus in the chronic stage oforganoarsenic poisoning.

Neuro-ophthalmology 34, 213, 2010109. Rosen RF, Tomidokoro Y, Ghiso JA, Walker LC: SDS-PAGE/immunoblot detection ofAβ multimers in human cortical tissue homogenates usingantigen-epitope retrieval.
Journal of Visualized Experiments Apr 23, 2010(38) pii: 1916.doi:10.3791/1916
110. Tomidokoro Y, Rostagno A, Neubert TA, Lu Y, Rebeck GW, Frangione B, Greenberg
SM, Ghiso J: Iowa variant of familial Alzheimerʼs disease: accumulation of posttranslationally
modiﬁed AβD23N in parenchymal and cerebrovascular amyloid deposits. American Journalof Pathology 176 (4): 1841- 1854, 2010
111.

Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K,

Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL,Mori H: A mouse model of amyloid β oligomers: their contribution to synaptic alteration,
abnormal tauphosphorylation, glial activation, and neuronal loss in vivo.

The Journal of

Neuroscience 30 (14): 4845-56, 2010112. Yokota O, Tsuchiya K, Arai T, YagishitaS, Matsubara O, Mochizuki A, Tamaoka A,
Yoshida H, Terada S, Ishizu H, Kuroda S, Akiyama H: Clinicopathological characterization offrontotemporal lobar degenerationwith ubiquitin-positive inclusions and Pickʼs disease Acta
Neuropathol 2009; 117(4): 429-444., 2009
113. Araki W, Kume H, Oda A, Tamaoka A, Kametani F: IGF-1 promotes beta-amyloid
production by a secretase-independent mechanism

Biochem Biophys Res Commun 2009;

380(1): 111-114, 2009114. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda

T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T,
Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T: Genomewide association study identiﬁes common variants at four loci as genetic risk factors
forParkinsonʼs disease Nature Genetics 41 (12): 1303-1307, 200
115.

Ishii A, Takuma H, Tsuji H, Ohkoshi N, Tamaoka A: Expression of TDP-43 in

inflammatory myopathies and other muscle diseases

Neuromuscl Disord 19: 651, 2009116. Ishii A, Shin JH, Katakai Y, Ono F, Okada T, Takeda S: Feasibility study of AAV8mediated gene therapy for muscular dystrophy using normal primate

Molecular Therapy

17: S361, 2009
117. Grinevich V, Kolleker A, Eliava M, Takada N, Takuma H, Fukazawa Y, Shigemoto R,
Kuhl D, Waters J, Seeburg PH, Osten P: TgArc/Arg3.1-d4EGFP indicator mice: a versatile
tool to study brain activity changes in vitro andin vivo J Neurosci Methods 184 (1), 25-36,
2009
118. Nakamagoe K, Ishii K, Tamaoka A: Abnormal ocular movements after organoarsenic
poisoning Journal of the Neurological Sciences, 285, Supplement 1, S140, 2009
119.

Kinoshita K, Noguchi A, Ishii K, Tamaoka A, Ochi T, Kaise T: Urine analysis ofpatients exposed to phenylarsenic compounds via accidental pollution J Chromatogr B Analyt
Technol Biomed Life Sci. 2008; 867(2): 179-88, 2008
120. Mizuta I, Tsunoda T, Satake W, Nakabayashi Y, Watanabe M, Takeda A, Hasegawa K,
Nakashima K, Yamamoto M, Hattori N, Murata M, Toda T: Calbindin1, ﬁbroblast growth
factor 20, and alpha- synuclein in sporadic Parkinsonʼs disease Human Genetics 124 (1):89-94, 2008
121.

Ishii A, Ohkoshi N, Tamaoka A: Expressions of FOXO1 and FOXO3a in skeletal

muscle atrophy associated with neuromusculardiseases (Neuromuscular Disorders 18, 789,2008)
122. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma
H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H:
A new amyloid β variant favoring oligomerization in Alzheimer-type Dementia (Annals of
Neurology 63 (3): 377-387, 2008)
123.

Takuma H, Teraoka R, Mori H, Tomiyama T: Amyloid β E22D variant induces

synaptic alteration in mouse hippocampal slices (Neuroreport 19 (6): 615-619, 2008)
124.

Berry A, Tomidokoro Y, Ghiso J, Thornton J: Human chorionic gonadotropin (aluteinizing hormone homologue) decreases spatial memory andincreases brain amyloid-betalevels in female rats (Horm Behav 54 (1): 143-152, 2008125. Miyazaki H, Oyama F, Wong HK, Kaneko K, Sakurai T, Tamaoka A, Nukina N: BACE1
modulates filopodia-like protrusions induced by sodium channel beta4 subunit Biochem

Biophys Res Commun. 2007 361(1): 43-8, 2007
126. Mizuno Y, Guyon JR, Ishii A, Hoshino S, Ohkoshi N, Tamaoka A, Okamoto K, Kunkel
LM: Beta- synemin expression in cardiotoxin-injected rat skeletal muscle BMC Musculoskelet
Disord. 2007 May 10; 8: 40, 2007
127. Aoyagi H, Hasegawa M, Tamaoka A: Fibrillogenic nuclei composed of P301L mutant
tau induce elongation of P301L tau, but not wild-type tau

J Biol Chem 2007 282(28):20309-18, 2007
128. Satake W, Mizuta I, Suzuki S, Nakabayashi Y, Ito C, Watanabe M, Takeda A, Hasegawa
K, Sakoda S, Yamamoto M, Hattori N, Murata M, Toda T: Fibro blast growth factor 20 geneand Parkinsonʼs disease in the Japanese population Neuroreport 18(9), 937-40, 2007
129.

Watanabe M, Takeda T, Tamaoka A: Sequential Imaging Analysis Using MIBG

Scintigraphy Revealed Progressive Degeneration of Cardiac Sympathetic Nervein Parkinsonʼs
Disease Neurodegenerative Diseases 4(suppl1), 133, 2007
130. Kobayashi S, Takuma H, Murayama S, Sakurai M, Kanazawa I: A Japanese family withearly-onset at axia with motor and sensory neuropathy

Journal of the Neurological

Sciences, 254, 44-48, 2007
131. Ishii A, Oda A, Tsuji H, Hosaka A, Ohkoshi N, Tamaoka A: A Family with autosomal
dominan there ditary sensory and autonomic neuropathy

Autonomic Neuroscience: Basic &Clinical135, 127, 2007
132.

Ishii A, Ohkoshi N, Tamaoka A: Expression of FOXO in inflammatory myositis(Neuromuscular Disord17, 886, 2007
133. Nakamagoe K, Ishii K, Tamaoka A, Shoji S: Oculomotor neural integrator failure inorganoarsenic poisoning

Neuro-Ophthalmology 30(6): 54, 2006

134. Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A: Drug interactionof tizanidine and ciproﬂoxacin: Case report

Clin Pharmacology & Therapeutics 2006;

80(6)715-720, 2006
135. Oyama F, Miyazaki H, Sakamoto N, Becquet C, Machida Y, Kaneko K, Uchikawa C,
Suzuki T, Kurosawa M, Ikeda T, Tamaoka A, Sakurai T, Nukina N: Sodium channel beta4
subunit: down- regulation and possible involvement in neuritic degeneration in Huntingtonʼsdisease transgenic mice J Neurochem. 2006; 98(2): 518-29, 2006
136.

NakamagoeK, Ishii K, Tamaoka A, Shoji S: Upward gaze-evoked nystagmus withorganoarsenic poisoning

Neurology 66(1): 131-132, 2006

137. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, Saito Y, Murayama
S: Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in
Alzheimerʼs disease brains J Neurosci Res. 54(1): 24-29, 2006
138. Watanabe M, Nakamura T, Honnda K, Ohkoshi N, Yoshizawa K, Yoshizawa T, Hayashi

A, Tamaoka A: DOPAMINED2RECEPTOR GENEPOLYMORPHISM AND THERISKOFLEVODOPAINDUCEDDYSKINESIASINJAPANESEPATIENTS

WITH

PARKINSONʼS DISEASE (PD) European Journal of Neurology 13(suppl2), 207, 2006
139.

Ishii K, Takeda T, Iwasaki N, Ishii K, Tsukada H, Tamaoka A: Effect of organo-arsiniccompoundsoncentralnervous systems

J Pharmacological Sciences 100(Suppl1), 27,2006
140. Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, Doi H,
Machida Y, Wong HK, Suzuki T, Uchikawa C, Kotliarov Y, Uchida K, Nagao Y, Nagaoka U,
Tamaoka A, Oyanagi K, Oyama F, Nukina N: Decreased expression of hypothalamic
neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP
ﬂuorescent aggregates J Neurochem. 2005 May; 93(3): 641-53, 2005
141.

Ishizaki M, Yanaoka T, Nakamura M, Hakuta T, Ueno S, Komuro M, Shibata M,

Kitamura T, Honda A, Doy M, Ishii K, Tamaoka A, Shimojo N, Ogata T, Nagasawa EHanaoka
S: Detection of bis(diphenylarsine) oxide, diphenylarsinic acid and phenylarsonic acid,compounds probably derived from chemical warfare agents, in drinking well water J Health
Science 51 (2): 130-137. 2005., 2005